Ajanta Pharma inks in-licensing deal with Biocon for Semaglutide marketing
Ajanta Pharma has entered an in-licensing agreement with Biocon for Semaglutide marketing across 26 countries in Africa, the Middle East, and Central Asia. The product patent expires in March 2026, with expected regulatory approvals in late 2026 or early 2027. Ajanta Pharma reported FY25 revenue of ₹4,648 crore.
The in-licensing agreement expands Ajanta Pharma's product portfolio into a high-growth therapeutic area and leverages their existing market reach. While significant, it is a marketing and distribution agreement, and the full impact will depend on regulatory approvals and market uptake.
The agreement with Biocon for a significant therapeutic product like Semaglutide, coupled with Ajanta Pharma's strong market presence and positive financial performance, suggests a positive outlook for the company.
Ajanta Pharma Limited has announced an in-licensing agreement with Biocon Limited for the marketing of Semaglutide, a GLP-1 receptor agonist. Under this agreement, Biocon will supply Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, the Middle East, and Central Asia.
Semaglutide is used to improve glycaemic control in adults. The product patent is set to expire in most of these markets in March 2026. Ajanta Pharma plans to launch the product commercially after obtaining regulatory approvals, which are anticipated in late 2026 or early 2027. Ajanta Pharma has a strong established branded generic business in over 30 countries across Africa, South-East Asia, Central Asia, and the Middle East, with a presence in various therapeutic segments.
Yogesh Agrawal, Managing Director of Ajanta Pharma Ltd., expressed excitement about partnering with Biocon, stating that GLP-1 therapies have seen rapid global acceptance and become blockbuster products. He is confident in building Semaglutide into a meaningful and high-growth brand in these regions.
Siddharth Mittal, CEO and MD of Biocon Ltd., highlighted that this partnership is a strategic step to expand the global footprint of Biocon’s GLP-1 portfolio and maximize value from their scientific investments. He also mentioned that the collaboration will enable broader and more affordable access to Semaglutide for patients in these regions.
For the fiscal year 2024-25, Ajanta Pharma reported a Revenue of ₹4,648 crore, EBIDTA of ₹1,260 crore (27%), and PAT of ₹920 crore (20%). The company has achieved a healthy revenue CAGR of 11% and a PAT CAGR of 25% over the last three financial years.
What to do with a filing like this
Ajanta Pharma Limited filed this with the NSE as a statutory disclosure, categorised under strategic partnerships. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ajanta Pharma Limited. Read the original for the full detail.